This trial is active, not recruiting.

Condition neoplasms
Treatments volasertib, itraconazole
Phase phase 1
Sponsor Boehringer Ingelheim
Start date February 2013
End date May 2014
Trial size 28 participants
Trial identifier NCT01772563, 1230.24, 2011-002367-23


The primary objective of the present study is to investigate the influence of co-administration of itraconazole and volasertib on the pharmacokinetic profile of volasertib without co-administration of itraconazole. Secondary objectives are to investigate safety, tolerability and preliminary therapeutic effects following intravenous administration of volasertib.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
administration of volasertib alone and in combination with itraconazole
cycle in 21 days
over 18 days

Primary Outcomes

area under the plasma concentration-time curve over the time interval from zero to the last quantifiable drug plasma concentration after dose administration (AUC0-tz)
time frame: up to 336 hours
maximum measured plasma concentration (Cmax)
time frame: up to 6 weeks

Secondary Outcomes

area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-infinity)
time frame: up to 6 weeks
number of participants with significant abnormalities in electrocardiogram results
time frame: up to 1 year
occurance of significant changes from baseline laboratory measurements
time frame: up to 1 year

Eligibility Criteria

All participants from 18 years up to 70 years old.

Inclusion criteria: 1. Patients with histologically or cytologically confirmed diagnosis of advanced, non resectable and / or metastatic solid tumour, for whom conventional treatment has failed, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment based on the investigator's assessment 2. Male or female 3. Age =>18 and =<70 years 4. Eastern Cooperative Oncology Group (ECOG) performance score =< 2 5. Recovery from Common Terminology Criteria for Adverse Events (CTCAE) Grade >= 2 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapy (except alopecia) Exclusion criteria: 1. Serious concomitant non-oncological disease considered by the investigator to be incompatible with the protocol 2. Active infectious disease 3. Viral hepatitis, HIV infection 4. Clinical evidence of active brain metastasis or leptomeningeal disease during the past 6 months 5. Second malignancy currently requiring active therapy (except for hormonal / antihormonal treatment e.g. in prostate or breast cancer) 6. Absolute neutrophil count less than 1,500/mm3 7. Platelet count less than 100,000/mm3 8. Total bilirubin greater than 1.5 mg/dL (> 26 µmol/L, SI unit equivalent) 9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal) 10. Serum creatinine greater than 2x upper limit of normal (ULN) 11. QTcF prolongation > 470 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the mean of the 3 ECGs taken at screening 12. Female patients with childbearing potential and unwilling to use a medically acceptable method of contraception during the trial and for at least six months after end of active therapy. Woman of childbearing potential (premenopausal female) is defined as the female who is not surgically sterilised by hysterectomy or bilateral tubal ligation or post-menopausal for at least 12 months. 13. Treatment with other investigational drugs or participation in another clinical trial within the past four weeks prior to start of therapy or concomitantly with this trial 14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy within the past four weeks prior to start of therapy or concomitantly with this trial. This restriction does not apply to steroids, bisphosphonates hormonal / antihormonal treatment (e.g. in prostate or breast cancer). 15. Alcohol abuse more than an average 3 units of alcoholic beverages per day or more than 21 units per week (1 unit equals 0.5 pint [285 mL] of beer or lager, 1 glass [125 mL] of wine, 25 mL shot of 40% spirit) or drug abuse 16. Life expectancy less than 12 weeks 17. Potent CYP 3A4 and P-glycoprotein inhibitors other than the study drug or inducers between one week prior to first drug administration or expected treatment with a respective drug until the last PK sample is collected 1. Strong CYP 3A4 inhibitors: atazanavir, clarithromycin, indinavir, itraconazole (other then study drug), ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin 2. CYP 3A4 inducers: carbamazepine, rifampicin 3. P-gp inhibitors: cyclosporine, erythromycin, itraconazole (other then study drug), ketoconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil 4. P-gp inducers: hypericum perforatum, rifampicin

Additional Information

Official title An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Boehringer Ingelheim.